PROGNOSTIC VALUE OF CEA, CA 19-9, CA 15-3, CA 125 AND AFP TUMOR MARKERS IN GASTROINTESTINAL AND BREAST MALIGNANT NEOPLASM PREOPERATIVE PATIENTS

Abstract

Biomarkers now play an important role in the detection and treatment of patients with gastrointestinal and breast malignant carcinoma. For this purpose, we investigated the main tumor markers CEA, CA 19-9, CA 15-3, CA 125 and AFP levels in preoperative patients, their prognostic significance and their relationships. Materials and Methods: CEA of 168 patients, 72 male and 96 female, diagnosed with preoperative gastrointestinal malignant neoplasm (colon, colorectal, rectum, secum, ileum, stomach and pancreas) and breast malignant neoplasm between October 2019 and December 2019, CA 19-9, CA 15-3, CA 125 and AFP test results were analyzed retrospectively. Results: Of 102 preoperative patients with gastrointestinal malign neoplasm included in the study, 72 were male (61%) and 30 were female (29%). In this patient group, 20 stomach, 45 colon, 12 rectum, 6 secum, 8 pancreas, 5 liver, 6 There were patients with malignant neoplasm of the duodenum (Table 2). The mean age of male patients was 63.1 ± 9.3, and the mean age of female patients was 66.3 ± 9.8. Conclusion:We concluded that in patients with gastrointestinal malignant neoplasm, the CEA tumor biomarker is an independent prognostic factor independent of CA 19-9 and AFP tests, while in preoperative patients with breast malignant neoplasm, CEA levels correlate consistent with the tumor biomarkers CA 15-3, CA 125.